ATE292964T1 - Verwendung von carboanhydrase-inhibitoren zur prävention von diabetischer retinopathie bei diabetikern - Google Patents

Verwendung von carboanhydrase-inhibitoren zur prävention von diabetischer retinopathie bei diabetikern

Info

Publication number
ATE292964T1
ATE292964T1 AT01958375T AT01958375T ATE292964T1 AT E292964 T1 ATE292964 T1 AT E292964T1 AT 01958375 T AT01958375 T AT 01958375T AT 01958375 T AT01958375 T AT 01958375T AT E292964 T1 ATE292964 T1 AT E292964T1
Authority
AT
Austria
Prior art keywords
diabetic
prevention
persons
diabetic retinopathy
carboanhydrase inhibitors
Prior art date
Application number
AT01958375T
Other languages
English (en)
Inventor
Einar Stefansson
Original Assignee
Einar Stefansson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Einar Stefansson filed Critical Einar Stefansson
Application granted granted Critical
Publication of ATE292964T1 publication Critical patent/ATE292964T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT01958375T 2000-08-11 2001-08-10 Verwendung von carboanhydrase-inhibitoren zur prävention von diabetischer retinopathie bei diabetikern ATE292964T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22435800P 2000-08-11 2000-08-11
PCT/IS2001/000015 WO2002013800A2 (en) 2000-08-11 2001-08-10 Method for the prevention and treatment of retinopathy

Publications (1)

Publication Number Publication Date
ATE292964T1 true ATE292964T1 (de) 2005-04-15

Family

ID=22840318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01958375T ATE292964T1 (de) 2000-08-11 2001-08-10 Verwendung von carboanhydrase-inhibitoren zur prävention von diabetischer retinopathie bei diabetikern

Country Status (7)

Country Link
US (1) US20020055458A1 (de)
EP (1) EP1307185B1 (de)
AT (1) ATE292964T1 (de)
AU (1) AU2001280093A1 (de)
CA (1) CA2419158A1 (de)
DE (1) DE60110087T2 (de)
WO (1) WO2002013800A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
EP1633353A1 (de) * 2003-05-30 2006-03-15 Merck & Co., Inc. Zusammensetzung und verfahren zur behandlung von makulastörungen
US8841259B2 (en) 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
US7670794B2 (en) * 2005-11-04 2010-03-02 Washington University Managing glycemia status in diabetic patients
US20070110707A1 (en) * 2005-11-04 2007-05-17 Washington University Method of treating diseases involving non-enzymatic glycation
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
CN101801375B (zh) 2007-01-25 2014-01-01 韦尔瓦制药有限公司 胰岛素增敏剂和治疗方法
MX2014014316A (es) * 2012-05-24 2015-07-06 Verva Pharmaceuticals Ltd Método de reducción de peso.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386098A (en) * 1981-11-03 1983-05-31 Merck & Co., Inc. 6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4677115A (en) * 1984-12-12 1987-06-30 Merck & Co., Inc. Antiglaucoma thieno-thiopyran and thieno-thiepin sulfonamide derivatives, compositions, and method of use thereof
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
EP1058546A4 (de) * 1998-03-06 2004-07-28 Univ Texas Zusammenstellungen und methoden zur behandlung von erkrankungen der macula
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions

Also Published As

Publication number Publication date
DE60110087T2 (de) 2005-09-29
EP1307185A2 (de) 2003-05-07
EP1307185B1 (de) 2005-04-13
CA2419158A1 (en) 2002-02-21
AU2001280093A1 (en) 2002-02-25
DE60110087D1 (de) 2005-05-19
WO2002013800A3 (en) 2002-05-02
WO2002013800A2 (en) 2002-02-21
US20020055458A1 (en) 2002-05-09

Similar Documents

Publication Publication Date Title
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
DE60317663D1 (de) Fluorchemische zusammensetzung enthaltend einen fluorierten polyether und dessen verwendung zur behandlung von fasermaterialien
DE60224718D1 (de) System zur hautpflege von benutzern von absorbierenden artikeln
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
EP1513924A4 (de) Attenuierte listeria spp. und verfahren zur verwendung davon
EE200300485A (et) Tiohüdantoinid ja nende kasutamine diabeedi raviks
ATE297380T1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE447552T1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
PT1246835E (pt) Sapogeninas substituídas e sua utilização
DK1327143T3 (da) Krystalstruktur af BACE og anvendelse deraf
ATE318821T1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
NO20064130L (no) Antineoplastiske kombinasjoner av CCI-779 og rituximab
AU2002359512A8 (en) Belts and methods of use thereof
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
AU2003226537A8 (en) Modulators of the notch signalling pathway and uses thereof in medical treatment
ATE292964T1 (de) Verwendung von carboanhydrase-inhibitoren zur prävention von diabetischer retinopathie bei diabetikern
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
EP1539134A4 (de) Nitrosierte und/oder nitrosylierte cyclooxygenase-2-selektive hemmer, zusammensetzungen und anwendungsverfahren
WO2003063725A3 (en) Methods of preventing and treating flavivirus infection in animals
HRP20050572A2 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60125212D1 (de) Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen.
SI1274450T1 (sl) Medicinske uporabe agonistov in antagonistov IL-174

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties